Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hardman Res.: R&D accelerated to advance assets

16th Oct 2017 10:42

RNS Number : 6904T
Avacta Group PLC
16 October 2017
 

Hardman Res.: R&D accelerated to advance assets

R&D accelerated to advance assets - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry, despite its limitations. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. Recent results highlighted significant progress made in its in-house therapeutic programmes with the first in-vivo studies showing safety, tolerability and efficacy of an Affimer. This adds to the de-risking of Affimer technology and attracting potential partners.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/16.10.17-r-d-accelerated-to-advance-assets.pdf

To contact us:

Contacts:

+44 20 7194 7622

Hardman & Co

Dr Martin Hall

[email protected]

35 New Broad Street

Dr Dorothea Hill

[email protected]

London

Dr Gregoire Pave

[email protected]

EC2M 1NH

 

 

Follow us on Twitter

@HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFFUSUMFWSEDS

Related Shares:

Avacta Group
FTSE 100 Latest
Value8,809.74
Change53.53